<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>REQUIP- ropinirole hydrochlorideÂ tablet, film coatedÂ </strong><br>GlaxoSmithKline LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use REQUIP safely and effectively. See full prescribing information for REQUIP.<br>REQUIP(ropinirole) tablets, for oral use <br>Initial U.S. Approval: 1997</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<table width="100%">
<col width="65%">
<col width="35%">
<tbody class="Headless">
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="Highlighta">Dosage and Administration (2.2, 2.3) </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="Highlighta">8/2014 </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="Highlighta">Warnings and Precautions (5.4, 5.6, 5.9) </p></td>
<td class="Botrule Lrule Rrule Toprule"><p class="Highlighta">8/2014 </p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">REQUIP is a non-ergoline dopamine agonist indicated for the treatment of Parkinsonâ€™s disease (PD) and moderate-to-severe primary <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS) (1.1, 1.2)  (<a href="#section-1">1</a>)</p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>REQUIPÂ Tablets can be taken with or without food (2.1)</dd>
<dt>â€¢</dt>
<dd>Retitration of REQUIP may be warranted if therapy is interrupted (2.1)</dd>
</dl>
<dl>
<dt>Â </dt>
<dd><span class="Bold">Parkinsonâ€™s Disease:</span></dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>The recommended starting dose is 0.25Â mg taken three times daily; titrate to a maximum daily dose of 24Â mg (2.2)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: The maximum recommended dose is 18 mg/day in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis (2.2) </dd>
</dl>
<dl>
<dt>Â </dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></span>: </dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>The recommended starting dose is 0.25 mg once daily, 1 to 3 hours before bedtime; titrate to a maximum recommended dose of 4Â mg daily (2.3)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: The maximum recommended dose is 3 mg/day in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis (2.3)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 0.25 mg, 0.5 mg, 1 mg, 2Â mg, 3Â mg, 4Â mg, and 5Â mg (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) to ropinirole or to any of the excipients (4)  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Sudden onset of sleep and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> may occur (5.1)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> may occur (5.2)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur (5.3)</dd>
<dt>â€¢</dt>
<dd>May cause <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behaviors (5.4)</dd>
<dt>â€¢</dt>
<dd>May cause or exacerbate <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> (5.5)</dd>
<dt>â€¢</dt>
<dd>May cause problems with impulse control or compulsive behaviors (5.6)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>Â </dt>
<dd>Most common adverse reactions (incidence with REQUIP at least 5% greater than placebo) in the respective indications were:</dd>
</dl>
<dl>
<dt>â€¢</dt>
<dd>Early PD: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, asthenic condition, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (6.1)</dd>
<dt>â€¢</dt>
<dd>Advanced PD: <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (6.1) </dd>
<dt>â€¢</dt>
<dd>RLS: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and asthenic condition. (6.1) </dd>
</dl>
<p class="Highlighta">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Inhibitors or inducers of CYP1A2: May alter the clearance of REQUIP; dose adjustment may be required (7.1, 12.3)</dd>
<dt>â€¢</dt>
<dd>Hormone replacement therapy (HRT): Starting or stopping HRT may require dose adjustment of REQUIP (7.2, 12.3)</dd>
<dt>â€¢</dt>
<dd>Dopamine antagonists (e.g., neuroleptics, metoclopramide): May reduce efficacy of REQUIP (7.3)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Pregnancy: Based on animal data, may cause fetal harm. (8.1)  (<a href="#section-8">8</a>)</p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Parkinsonâ€™s Disease</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 General Dosing Recommendations</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosing for Parkinsonâ€™s Disease</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosing for <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep during Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> </a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-like Behavior</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Impulse Control/Compulsive Behaviors</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Withdrawal-emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Melanoma</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Augmentation and Early-morning Rebound in <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Fibrotic Complications</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Retinal Pathology</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Binding to Melanin</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP1A2 Inhibitors and Inducers</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Estrogens </a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Dopamine Antagonists</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Parkinsonâ€™s Disease </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_9dcb7022-fdc3-413b-8619-f057c4891f22"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1f3c03a8-d222-47bd-8309-e82c9444e0b7"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Parkinsonâ€™s Disease</h2>
<p class="First">REQUIP<span class="Sup">Â®</span> is indicated for the treatment of Parkinsonâ€™s disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_cd9d4137-4dd7-4538-91b3-04f051fccdd3"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></h2>
<p class="First">REQUIP is indicated for the treatment of moderate-to-severe primary <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_4665cce2-268d-413d-88ea-1202a8ede6c0"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">REQUIP can be taken with or without food <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<p>If a significant interruption in therapy with REQUIP has occurred, retitration of therapy may be warranted.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_141b9773-2670-43ce-91fb-cb467e0c738f"></a><a name="section-2.1"></a><p></p>
<h2>2.1 General Dosing Recommendations</h2>
<p class="First">REQUIP can be taken with or without food <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<p>If a significant interruption in therapy with REQUIP has occurred, retitration of therapy may be warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a686da46-7a14-4e38-abc5-2fd72b8b0025"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosing for Parkinsonâ€™s Disease</h2>
<p class="First">The recommended starting dose for Parkinsonâ€™s disease is 0.25Â mg three times daily. Based on individual patient therapeutic response and tolerability, if necessary, the dose should then be titrated with weekly increments as described in TableÂ 1. After Week 4, if necessary, the daily dose may be increased by 1.5Â mg/day on a weekly basis up to a dose of 9Â mg/day, and then by up to 3Â mg/day weekly up to a maximum recommended total daily dose of 24Â mg/day (8 mg three times daily). Doses greater than 24Â mg/day have not been tested in clinical trials.</p>
<table width="100%">
<caption><span>Table 1. Ascending-dose Schedule of REQUIP for Parkinsonâ€™s Disease</span></caption>
<col width="10%">
<col width="37%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Week</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Dosage</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Total Daily Dose</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">1</p></td>
<td class="Lrule Rrule" align="center" valign="bottom"><p class="First">0.25Â mg 3 times daily</p></td>
<td class="Lrule Rrule" align="center" valign="bottom"><p class="First">0.75Â mg</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">2</p></td>
<td class="Lrule Rrule" align="center" valign="bottom"><p class="First">0.5Â mg 3 times daily</p></td>
<td class="Lrule Rrule" align="center" valign="bottom"><p class="First">1.5Â mg</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center" valign="bottom"><p class="First">0.75Â mg 3 times daily</p></td>
<td class="Lrule Rrule" align="center" valign="bottom"><p class="First">2.25Â mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">1Â mg 3 times daily</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">3Â mg</p></td>
</tr>
</tbody>
</table>
<p>REQUIP should be discontinued gradually over a 7-day period in patients with Parkinsonâ€™s disease. The frequency of administration should be reduced from three times daily to twice daily for 4Â days. For the remaining 3Â days, the frequency should be reduced to once daily prior to complete withdrawal of REQUIP.</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">No dose adjustment is necessary in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 30 to 50 mL/min). The recommended initial dose of ropinirole for patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis is 0.25Â mg three times a day. Further dose escalations should be based on tolerability and need for efficacy. The recommended maximum total daily dose is 18Â mg/day in patients receiving regular dialysis. Supplemental doses after dialysis are not required. The use of REQUIP in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> without regular dialysis has not been studied.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b5be89d9-b360-4f76-9dd2-634254184fb5"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosing for <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></h2>
<p class="First">The recommended adult starting dose for RLS is 0.25Â mg once daily 1 to 3 hours before bedtime. After 2Â days, if necessary, the dose can be increased to 0.5Â mg once daily, and to 1Â mg once daily at the end of the first week of dosing, then as shown in TableÂ 2 as needed to achieve efficacy. Titration should be based on individual patient therapeutic response and tolerability, up to a maximum recommended dose of 4 mg daily. For RLS, the safety and effectiveness of doses greater than 4Â mg once daily have not been established. </p>
<table width="100%">
<caption><span>Table 2. Dose Titration Schedule of REQUIP for <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></span></caption>
<col width="35%">
<col width="45%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Day/Week</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Dose to be taken once daily</span></p>
<p><span class="Bold">1 to 3 hours before bedtime</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Days 1 and 2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.25 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Days 3 â€“ 7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">0.5 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Week 2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Week 3</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">1.5 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Week 4</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Week 5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">2.5 mg</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Week 6</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">3 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">Week 7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">4 mg</p></td>
</tr>
</tbody>
</table>
<p>In clinical trials of patients treated for RLS with doses up to 4 mg once daily, REQUIP was discontinued without a taper.</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">No dose adjustment is necessary in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 30 to 50 mL/min). The recommended initial dose of ropinirole for patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis is 0.25 mg once daily. Further dose escalations should be based on tolerability and need for efficacy. The recommended maximum total daily dose is 3 mg/day in patients receiving regular dialysis. Supplemental doses after dialysis are not required. The use of REQUIP in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> without regular dialysis has not been studied.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_fad08b88-a223-48cb-bc8e-bab707a41361"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>â€¢</dt>
<dd>0.25 mg, white, film-coated tablet, imprinted with â€œSBâ€? and â€œ4890â€?</dd>
<dt>â€¢</dt>
<dd>0.5Â mg, yellow, film-coated tablet, imprinted with â€œSBâ€? and â€œ4891â€?</dd>
<dt>â€¢</dt>
<dd>1Â mg, green, film-coated tablet, imprinted with â€œSBâ€? and â€œ4892â€?</dd>
<dt>â€¢</dt>
<dd>2Â mg, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellowishâ€‘pink, film-coated tablet, imprinted with â€œSBâ€? and â€œ4893â€?</dd>
<dt>â€¢</dt>
<dd>3Â mg, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> to moderate reddish-purple, film-coated tablet, imprinted with â€œSBâ€? and â€œ4895â€?</dd>
<dt>â€¢</dt>
<dd>4Â mg, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> brown, film-coated tablet, imprinted with â€œSBâ€? and â€œ4896â€?</dd>
<dt>â€¢</dt>
<dd>5Â mg, blue, film-coated tablet imprinted with â€œSBâ€? and â€œ4894â€?</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_3d23c4b4-1bb8-40e2-8c85-867b3bbbc062"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">REQUIP is contraindicated in patients known to have a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) to ropinirole or to any of the excipients.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_e22911e9-813d-4bdd-93c4-d3a9456a2cf4"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c27665e3-e58f-4ec3-a170-6c335d475af7"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep during Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></h2>
<p class="First">Patients treated with REQUIP have reported <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living, including driving or operating machinery, which sometimes resulted in <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>. Although many of these patients reported <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> while on REQUIP, some perceived that they had no warning signs, such as excessive <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and believed that they were alert immediately prior to the event. Some have reported these events more than 1 year after initiation of treatment.</p>
<p>In controlled clinical trials, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was commonly reported in patients receiving REQUIP and was more frequent in Parkinson's disease (up to 40% REQUIP, 6% placebo) than in <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (12% REQUIP, 6% placebo)<span class="Italics">[see Adverse Reactions (6.1)]</span>.</p>
<p>It has been reported that <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living usually occurs in a setting of preexisting <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, although patients may not give such a history. For this reason, prescribers should reassess patients for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>, especially since some of the events occur well after the start of treatment. Prescribers should also be aware that patients may not acknowledge <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> until directly questioned about <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> during specific activities.</p>
<p>Before initiating treatment with REQUIP, patients should be advised of the potential to develop <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and specifically asked about factors that may increase the risk with REQUIP such as concomitant sedating medications, the presence of <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorders</span> (other than RLS), and concomitant medications that increase ropinirole plasma levels (e.g., ciprofloxacin) <span class="Italics">[see Drug Interactions (7.1)]</span>. If a patient develops significant <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">daytime sleepiness</span> or episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep during activities that require active participation (e.g., driving a motor vehicle, conversations, eating), REQUIP should ordinarily be discontinued <span class="Italics">[see Dosage and Administration (2.2, 2.3)]</span>. If a decision is made to continue REQUIP, patients should be advised to not drive and to avoid other potentially dangerous activities. There is insufficient information to establish that dose reduction will eliminate episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e4d8a960-87e8-402a-be53-12f22438cc4a"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, sometimes associated with <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, was observed in association with ropinirole in both patients with Parkinsonâ€™s disease and patients with RLS. In controlled clinical trials in patients with Parkinsonâ€™s disease, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was observed more frequently in patients receiving REQUIP than in patients receiving placebo (early Parkinsonâ€™s disease without L-dopa: REQUIP 12%, placebo 1%; advanced Parkinsonâ€™s disease: REQUIP 3%, placebo 2%). <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> was reported in 1% of patients treated with REQUIP for RLS in 12-week, placebo-controlled clinical trials compared with 0.2% of patients treated with placebo<span class="Italics">[see Adverse Reactions (6.1)]</span>. Most cases occurred more than 4 weeks after initiation of therapy with REQUIP, and were usually associated with a recent increase in dose.</p>
<p>Because the trials of REQUIP excluded patients with significant cardiovascular disease, patients with significant cardiovascular disease should be treated with caution.</p>
<p>Approximately 4% of patients with Parkinsonâ€™s disease enrolled in Phase 1 trials had <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> following a 1-mg dose of REQUIP. In two trials in patients with RLS that used a forced-titration regimen and orthostatic challenge with intensive blood pressure monitoring, 2% of RLS patients treated with REQUIP compared with 0% of patients receiving placebo reported <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p>In Phase 1 trials including healthy volunteers, the incidence of <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was 2%. Of note, 1 subject with <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> developed <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span>; the subject recovered spontaneously without intervention.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f836e9f2-8ebc-4bb8-ae3f-6aef34689f4e"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> </h2>
<p class="First">Dopamine agonists in clinical trials and clinical experience appear to impair the systemic regulation of blood pressure, with resulting <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, especially during dose escalation. In addition, patients with Parkinsonâ€™s disease appear to have an impaired capacity to respond to a postural challenge. For these reasons, patients should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, especially during dose escalation, and patients should be informed of the risk for <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="Italics">[see Patient Counseling Information (17)]</span>. </p>
<p>Although the clinical trials were not designed to systematically monitor blood pressure, there were individual reported cases of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in early Parkinsonâ€™s disease (without L-dopa) in patients treated with REQUIP. Most of these cases occurred more than 4Â weeks after initiation of therapy with REQUIP and were usually associated with a recent increase in dose.</p>
<p>In 12-week, placebo-controlled trials of patients with RLS, the adverse event <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> was reported by 4 of 496 patients (0.8%) treated with REQUIP compared with 2 of 500 patients (0.4%) receiving placebo.</p>
<p>In two Phase 2 studies in patients with RLS, 14 of 55 patients (25%) receiving REQUIP experienced an adverse event of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> compared with none of the 27 patients receiving placebo. In these studies, 11 of the 55 patients (20%) receiving REQUIP and 3 of the 26 patients (12%) who had post-dose blood pressure assessments following placebo, experienced an orthostatic blood pressure decrease of at least 40 mm Hg systolic and/or at least 20 mm Hg diastolic.</p>
<p>In Phase 1 trials of REQUIP with healthy volunteers who received single doses on morethan one occasion without titration, 7% had documented symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>. These episodes appeared mainly at doses above 0.8Â mg and these doses are higher than the starting doses recommended for patients with either Parkinsonâ€™s disease or with RLS. In most of these individuals, the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was accompanied by <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> but did not develop into <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>. </p>
<p>Although <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> is not a specific manifestation of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, patients with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> frequently reported <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. In controlled clinical trials, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was a common adverse reaction in patients receiving REQUIP and was more frequent in patients with Parkinsonâ€™s disease or with RLS receiving REQUIP than in patients receiving placebo (early Parkinsonâ€™s disease without L-dopa: REQUIP 40%, placebo 22%; advanced Parkinsonâ€™s disease: REQUIP 26%, placebo 16%; RLS: REQUIP 11%, placebo 5%). <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> of sufficient severity to cause trial discontinuation of REQUIP was 4% in patients with early Parkinsonâ€™s disease without L-dopa, 3% in patients with advanced Parkinsonâ€™s disease, and 1% in patients with RLS. <span class="Italics">[See Adverse Reactions (6.1).]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_93cb80c3-4ba1-487c-91c5-f2a29ac71195"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-like Behavior</h2>
<p class="First">In double-blind, placebo-controlled, early-therapy trials in patients with Parkinsonâ€™s disease who were not treated with L-dopa, 5.2% (8 of 157) of patients treated with REQUIP reported <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, compared with 1.4% of patients on placebo (2 of 147). Among those patients receiving both REQUIP and L-dopa in advanced Parkinsonâ€™s disease studies, 10.1% (21 of 208) were reported to experience <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, compared with 4.2% (5 of 120) of patients treated with placebo and L-dopa. </p>
<p>The incidence of <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span> was increased in elderly patients (i.e., older than 65 years) treated with extended-release REQUIP <span class="Italics">[see Use in Specific Populations (8.5)]</span>.</p>
<p style="border-left:1px solid;"><span class="XmChange">Postmarketing reports indicate that patients may experience new or worsening mental status and behavioral changes, which may be severe, including <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior during treatment with REQUIP or after starting or increasing the dose of REQUIP. Other drugs prescribed to improve the symptoms of Parkinsonâ€™s disease can have similar effects on thinking and behavior. This <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> and behavior can consist of one or more of a variety of manifestations including paranoid ideation, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, and <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>.</span></p>
<p>Patients with a major <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic disorder</span> should ordinarily not be treated with REQUIP because of the risk of exacerbating the <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. In addition, certain medications used to treat <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> may exacerbate the symptoms of Parkinsonâ€™s disease and may decrease the effectiveness of REQUIP <span class="Italics">[see</span><span class="Italics">Drug Interactions (7.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e12fec51-e017-4321-b007-8022dd83c330"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></h2>
<p class="First">REQUIP may potentiate the dopaminergic side effects of L-dopa and may cause and/or exacerbate pre-existing <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> in patients treated with L-dopa for Parkinsonâ€™s disease. In double-blind, placebo-controlled trials in advanced Parkinsonâ€™s disease, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span> was much more common in patients treated with REQUIP than in those treated with placebo. Among those patients receiving both REQUIP and L-dopa in advanced Parkinsonâ€™s disease trials, 34% were reported to experience <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, compared with 13% of patients treated with placebo <span class="Italics">[see Adverse Reactions (6.1)].</span>Decreasing the dose of the dopaminergic drug may ameliorate this adverse reaction.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8a426495-47ea-4db6-b709-a0e60ba131e3"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Impulse Control/Compulsive Behaviors</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Case reports suggest that patients can experience intense urges to gamble, increased sexual urges, intense urges to spendmoney, binge or compulsive eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including REQUIP, that increase central dopaminergic tone and that are generally used for the treatment of Parkinsonâ€™s disease and RLS. In some cases, although not all, these urges were reported to have stopped when the dose was reduced or the medication was discontinued. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased <span class="product-label-link" type="condition" conceptid="4023166" conceptname="Gambling">gambling</span> urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while being treated with REQUIP. Physiciansshould consider dose reduction or stopping the medication if a patient develops such urges while taking REQUIP.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7d5a60f3-e7be-4512-bc20-b707d15851e4"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Withdrawal-emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></h2>
<p class="First">A symptom complex resembling the <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span> (characterized by elevated temperature, muscular <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, altered consciousness, and <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span>), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. Therefore, it is recommended that the dose be tapered at the end of treatment with REQUIP for Parkinsonâ€™s disease as a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> measure <span class="Italics">[see Dosage and Administration (2.2)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_91a57eae-16f0-4165-a350-32f0c2eb8612"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Melanoma</h2>
<p class="First">Epidemiological studies have shown that patients with Parkinsonâ€™s disease have a higher risk (2- to approximately 6-fold higher) of developing melanoma than the general population. Whether the increased risk observed was due to Parkinsonâ€™s disease or other factors, such as drugs used to treat Parkinsonâ€™s disease, is unclear. </p>
<p>For the reasons stated above, patients and providers are advised to monitor for melanomas frequently and on a regular basis when using REQUIP for any indication. Ideally, periodic skin examinations should be performed by appropriately qualified individuals (e.g., dermatologists).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9d7978c0-b0d8-4c4f-8eaf-475bd55a5c3a"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Augmentation and Early-morning Rebound in <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Reports in the literature indicate treatment of RLS with dopaminergic medications can result in recurrence of symptoms in the early morning hours, referred to as rebound. Augmentation has also been described during therapy for RLS. Augmentation refers to the earlier onset of symptoms in the evening (or even the afternoon), increase in symptoms, and spread of symptoms to involve other extremities. Rebound refers to new onset of symptoms in the early morning hours. Augmentation and/or early-morning rebound have been observed in a postmarketing trial. If augmentation or early-morning rebound occurs, the use of REQUIP should be reviewed and dosage adjustment or discontinuation of treatment should be considered.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9b571063-2ef2-46a8-b08c-7bf9b8e20ba9"></a><a name="section-5.10"></a><p></p>
<h2>5.10 Fibrotic Complications</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">retroperitoneal fibrosis</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="4050884" conceptname="Pleural plaque">pleural thickening</span>, <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">pericarditis</span>, and <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">cardiac valvulopathy</span> have been reported in some patients treated with ergot-derived dopaminergic agents. While these complications may resolve when the drug is discontinued, complete resolution does not always occur.</p>
<p>Although these adverse reactions are believed to be related to the ergoline structure of these compounds, whether other, non-ergotâ€‘derived dopamine agonists such as ropinirole can cause them is unknown.</p>
<p>Cases of possible fibrotic complications, including <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span>, <span class="product-label-link" type="condition" conceptid="4050884" conceptname="Pleural plaque">pleural fibrosis</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial lung disease</span>, and <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">cardiac valvulopathy</span> have been reported in the development program and postmarketing experience for ropinirole. While the evidence is not sufficient to establish a causal relationship between ropinirole and these fibrotic complications, a contribution of ropinirole cannot be excluded.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_00ef2b48-8cac-4e30-b965-dd2d5db93e85"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Retinal Pathology</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">Retinal degeneration</span> was observed in albino rats in the 2-year carcinogenicity study at all doses tested (equivalent to 0.6 to 20Â times the maximum recommended human dose [MRHD] for Parkinsonâ€™s disease [24 mg/day] on a mg/m<span class="Sup">2</span> basis), but was statistically significant at the highest dose (50Â mg/kg/day). <span class="product-label-link" type="condition" conceptid="4090255" conceptname="Retinal drusen">Retinal degeneration</span> was not observed in a 3-month study in pigmented rats, in a 2-year carcinogenicity study in albino mice, or in 1â€‘year studies in monkeys or albino rats. The significance of this effect for humans has not been established but involves disruption of a mechanism that is universally present in vertebrates (e.g., disk shedding).</p>
<p>Ocular electroretinogram (ERG) assessments were conducted during a 2-year, double-blind, multicenter, flexible dose, L-dopa-controlled clinical trial of ropinirole in patients with Parkinsonâ€™s disease; 156 patients (78 on ropinirole, mean dose: 11.9 mg/day, and 78 on L-dopa, mean dose: 555.2 mg/day) were evaluated for evidence of retinal dysfunction through electroretinograms. There was no clinically meaningful difference between the treatment groups in retinal function over the duration of the trial.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7a4e641e-976e-4967-9ee5-00b07be53049"></a><a name="section-5.12"></a><p></p>
<h2>5.12 Binding to Melanin</h2>
<p class="First">Ropinirole binds to melanin-containing tissues (i.e., eyes, skin) in pigmented rats. After a single dose, long-term retention of drug was demonstrated, with a half-life in the eye of 20Â days</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_5ac3a3b6-1c79-4de4-b1bb-f5eda660cb54"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described in more detail in other sections of the label:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> <span class="Italics">[see Contraindications (4)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep during Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> <span class="Italics">[see Warnings and Precautions (5.1)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> <span class="Italics">[see Warnings and Precautions (5.2)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span> <span class="Italics">[see Warnings and Precautions (5.3)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-like Behavior <span class="Italics">[see Warnings and Precautions (5.4)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span> <span class="Italics">[see Warnings and Precautions (5.5)]</span>
</dd>
<dt>â€¢</dt>
<dd>Impulse Control/Compulsive Behaviors <span class="Italics">[see Warnings and Precautions (5.6)]</span>
</dd>
<dt>â€¢</dt>
<dd>Withdrawal-emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span> <span class="Italics">[see Warnings and Precautions (5.7)]</span>
</dd>
<dt>â€¢</dt>
<dd>Melanoma <span class="Italics">[see Warnings and Precautions (5.8)]</span>
</dd>
<dt>â€¢</dt>
<dd>Augmentation and Early-morning rebound in RLS<span class="Italics"> [see Warnings and Precautions (5.9)]</span>
</dd>
<dt>â€¢</dt>
<dd>Fibrotic Complications <span class="Italics">[see Warnings and Precautions (5.10)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6c5c0dcc-bfa0-48c2-9372-541152593c6d"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug (or of another development program of a different formulation of the same drug) and may not reflect the rates observed in practice.</p>
<p><span class="Underline">Parkinsonâ€™s Disease</span></p>
<p>During the premarketing development of REQUIP, patients received REQUIP either without L-dopa (early Parkinsonâ€™s disease trials) or as concomitant therapy with L-dopa (advanced Parkinsonâ€™s disease trials). Because these two populations may have differential risks for various adverse reactions, this section will in general present adverse reaction data for these twoÂ populations separately.</p>
<p><span class="Italics">Early Parkinsonâ€™s Disease (without L-dopa)</span></p>
<p>In the double-blind, placebo-controlled trials in patients with early-stage Parkinsonâ€™s disease, the most commonly observed adverse reactions in patients treated with REQUIP (incidence at least 5% greater than placebo) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, asthenic condition (i.e., <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and/or <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>), <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>. </p>
<p>Approximately 24% of patients treated with REQUIP who participated in the double-blind, placebo-controlled early Parkinsonâ€™s disease (without L-dopa) trials discontinued treatment due to adverse reactions compared with 13% of patients who received placebo. The most common adverse reactions in patients treated with REQUIP (incidence at least 2% greater than placebo) of sufficient severity to cause discontinuation were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. </p>
<p>TableÂ 3 lists treatment-emergent adverse reactions that occurred in at least 2% of patients with early Parkinsonâ€™s disease (without L-dopa) treated with REQUIP participating in the double-blind, placebo-controlled trials and were numerically more common than the incidence for placebo-treated patients. In these trials, either REQUIP or placebo was used as early therapy (i.e., without L-dopa).</p>
<table width="100%">
<caption><span>Table 3. Treatment-emergent Adverse Reaction Incidence in Double-blind, Placebo-controlled Early Parkinsonâ€™s Disease (without L-dopa) Trials (Events â‰¥2% of Patients Treated with REQUIP and Numerically More Frequent than the Placebo Group)<span class="Sup">a</span></span></caption>
<col width="45%">
<col width="26%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Body System/Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">REQUIP</span></p>
<p><span class="Bold">(nÂ =Â 157)</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =Â 147)</span></p>
<p><span class="Bold">(%)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Autonomic nervous system</p></td>
<td class="Lrule Rrule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd>Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Body as a whole</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd>Asthenic condition<span class="Sup">b</span>
</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">16</p></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Leg edema</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">8</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Cardiovascular general</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd>Orthostatic symptoms</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Central/peripheral nervous system</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">40</p></td>
<td class="Rrule" align="center"><p class="First">22</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypesthesia</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Gastrointestinal</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">10</p></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">60</p></td>
<td class="Rrule" align="center"><p class="First">22</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Heart rate/rhythm</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">Extrasystoles</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule"><p class="First">Metabolic/nutritional</p></td>
<td class="Lrule Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd>Increased alkaline phosphatase</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Psychiatric</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd>Impaired concentration</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">40</p></td>
<td class="Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">Yawning</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Reproductive male</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Resistance mechanism</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infection</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Respiratory </p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Urinary </p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Vascular extracardiac</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">Peripheral ischemia</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Toprule"><p class="First">Vision</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye abnormality</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">Xerophthalmia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Patients may have reported multiple adverse reactions during the trial or at discontinuation; thus, patients may be included in more than one category.</p>
<p><span class="Sup">b</span>	Asthenic condition (i.e., <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and/or <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>).</p>
<p>Advanced Parkinsonâ€™s Disease (with L-dopa)</p>
<p>In the double-blind, placebo-controlled trials in patients with advanced-stage Parkinsonâ€™s disease, the most commonly observed adverse reactions in patients treated with REQUIP (incidence at least 5 % greater than placebo) were <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>Approximately 24% of patients who received REQUIP in the double-blind, placebo-controlled advanced Parkinsonâ€™s disease (with L-dopa) trials discontinued treatment due to adverse reactions compared with 18% of patients who received placebo. The most common adverse reaction in patients treated with REQUIP (incidence at least 2% greater than placebo) of sufficient severity to cause discontinuation was <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>Table 4 lists treatment-emergent adverse reactions that occurred in at least 2% of patients with advanced Parkinsonâ€™s disease (with L-dopa) treated with REQUIP who participated in the double-blind, placebo-controlled trials and were numerically more common than the incidence for placebo-treated patients. In these trials, either REQUIP or placebo was used as an adjunct to L-dopa.</p>
<table width="100%">
<caption><span>Table 4. Treatment-emergent Adverse Reaction Incidence in Double-blind, Placebo-controlled Advanced Parkinsonâ€™s Disease (with L-dopa) Trials (Events â‰¥2% of Patients Treated with REQUIP and Numerically More Frequent than the Placebo Group)<span class="Sup">a</span></span></caption>
<col width="48%">
<col width="26%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Body System/Adverse Reaction</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">REQUIP</span></p>
<p><span class="Bold">(nÂ =Â 208)</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =Â 120)</span></p>
<p><span class="Bold">(%)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Autonomic nervous system</p></td>
<td class="Rrule"></td>
<td class="Rrule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Body as a whole</p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Increased drug level</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">7</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">5</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Cardiovascular general</p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Central/peripheral nervous system</p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">26</p></td>
<td class="Rrule" align="center"><p class="First">16</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">34</p></td>
<td class="Rrule" align="center"><p class="First">13</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falls</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">10</p></td>
<td class="Rrule" align="center"><p class="First">7</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">17</p></td>
<td class="Rrule" align="center"><p class="First">12</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">Hypokinesia</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4154696" conceptname="Spastic paresis">Paresis</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Gastrointestinal </p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">9</p></td>
<td class="Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">30</p></td>
<td class="Rrule" align="center"><p class="First">18</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Increased saliva</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Metabolic/nutritional</p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Musculoskeletal </p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">7</p></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Psychiatric</p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">9</p></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Abnormal dreaming</dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucination</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">10</p></td>
<td class="Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">5</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">20</p></td>
<td class="Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Red blood cell</p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Resistance mechanism</p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Respiratory </p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><p class="First">Urinary </p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4167328" conceptname="Pyuria">Pyuria</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">2</p></td>
<td class="Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></dd>
</dl></td>
<td class="Rrule" align="center"><p class="First">6</p></td>
<td class="Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Vision</p></td>
<td class="Rrule Toprule"></td>
<td class="Rrule Toprule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></dd>
</dl></td>
<td class="Botrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">1</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Patients may have reported multiple adverse reactions during the trial or at discontinuation; thus, patients may be included in more than one category.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></span></p>
<p>In the double-blind, placebo-controlledtrials in patients with RLS, the most commonly observed adverse reactions in patients treated with REQUIP (incidence at least 5% greater than placebo) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and asthenic condition (i.e., <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and/or <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>).</p>
<p>Approximately 5% of patients treated with REQUIP who participated in the double-blind, placebo-controlled trials in the treatment of RLS discontinued treatment due to adverse reactions compared with 4% of patients who received placebo. The most common adverse reaction in patients treated with REQUIP (incidence at least 2% greater than placebo) of sufficient severity to cause discontinuation was <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
<p>Table 5 lists treatment-emergent adverse reactions that occurred in at least 2% of patients with RLS treated with REQUIP participating in the 12-week, double-blind, placebo-controlled trials and were numerically more common than the incidence for placebo-treated patients. </p>
<table width="100%">
<caption><span>Table 5. Treatment-emergent Adverse Reaction Incidence in Double-blind, Placebo-controlled RLS Trials (Events â‰¥2% of Patients Treated with REQUIP and Numerically More Frequent than the Placebo Group)<span class="Sup">a</span></span></caption>
<col width="49%">
<col width="25%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Body System/Adverse Reaction</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">REQUIP</span></p>
<p><span class="Bold">(nÂ =Â 496)</span></p>
<p><span class="Bold">(%)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Placebo</span></p>
<p><span class="Bold">(nÂ =500)</span></p>
<p><span class="Bold">(%)</span></p>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Ear and labyrinth </p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Gastrointestinal </p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">40</p></td>
<td class="Lrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">5</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">General disorders and administration site conditions</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd>Asthenic condition<span class="Sup">b</span>
</dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">9</p></td>
<td class="Lrule Rrule" align="center"><p class="First">8</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Musculoskeletal and connective tissue </p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">4</p></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Nervous system </p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">12</p></td>
<td class="Lrule Rrule" align="center"><p class="First">6</p></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">11</p></td>
<td class="Lrule Rrule" align="center"><p class="First">5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Respiratory, thoracic, and mediastinal </p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></dd>
</dl></td>
<td class="Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Lrule Rrule" align="center"><p class="First">2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><p class="First">Skin and subcutaneous tissue</p></td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></dd>
</dl></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span>Patients may have reported multiple adverse reactions during the trial or at discontinuation; thus, patients may be included in more than one category.</p>
<p><span class="Sup"> b</span>	Asthenic condition (i.e., <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and/or <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_9d9cbd43-472f-4b23-811e-7f415b10d0ea"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_04ac7e68-7281-4e0f-89eb-2b562331ecbf"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP1A2 Inhibitors and Inducers</h2>
<p class="First">In vitro metabolism studies showed that CYP1A2 is the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for inducers or inhibitors of this enzyme to alter the clearance of ropinirole. Therefore, if therapy with a drug known to be a potent inducer or inhibitor of CYP1A2 is stopped or started during treatment with REQUIP, adjustment of the dose of REQUIP may be required. Coadministration of ciprofloxacin, an inhibitor of CYP1A2, increases the AUC and C<span class="Sub">max</span> of ropinirole <span class="Italics">[see Clinical Pharmacology (12.3)]. </span>Cigarette smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking<span class="Italics"> [see Clinical Pharmacology (12.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_183ebed6-310e-4339-8537-446dfbcc3cb7"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Estrogens </h2>
<p class="First">Population pharmacokinetic analysis revealed that higher doses of estrogens (usually associated with hormone replacement therapy [HRT]) reduced the clearance of ropinirole. Starting or stopping HRT may require adjustment of dosage of REQUIP <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e044329b-73ea-4748-84b8-b498cc913735"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Dopamine Antagonists</h2>
<p class="First">Because ropinirole is a dopamine agonist, it is possible that dopamine antagonists such as neuroleptics (e.g., phenothiazines, butyrophenones, thioxanthenes) or metoclopramide may reduce the efficacy of REQUIP.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_d387be42-af89-4424-8268-38dadafc897d"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_dd219da4-d0a9-4c2b-847b-f711370c3768"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Underline">Pregnancy Category C.</span> There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, ropinirole has been shown to have adverse effects on embryo-fetal development, including teratogenic effects. REQUIP should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. </p>
<p>Oral treatment of pregnant rats with ropinirole during organogenesis resulted in decreased fetal body weight, increased <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, and digital malformations at 24, 36, and 60 times, respectively, the maximum recommended human dose (MRHD) for Parkinsonâ€™s disease (24 mg/day) on a mg/m<span class="Sup">2</span> basis. The combined oral administration of ropinirole at 8Â times the MRHD and a clinically relevant dose of Lâ€‘dopa to pregnant rabbits during organogenesis produced a greater incidence and severity of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (primarily digit defects) than were seen in the offspring of rabbits treated with L-dopa alone. No effect on fetal development was observed in rabbits when ropinirole was administered alone at an oral dose 16Â times the MRHD on a mg/m<span class="Sup">2</span> basis. In a perinatal-postnatal study in rats, impaired growth and development of nursing offspring and altered neurological development of female offspring were observed when dams were treated with 4 times the MRHD on a mg/m<span class="Sup">2</span> basis.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_4b6b5d2d-a954-4dde-bfbe-6f76b6c25029"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Ropinirole inhibits prolactin secretion in humans and could potentially inhibit lactation. Ropinirole has been detected in rat milk. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when REQUIP is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_608f74f2-e813-403a-9f25-856192c259ed"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_82e76e1e-58ca-4c07-af07-8a961f7ebc9b"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Dose adjustment is not necessary in elderly (65Â years and older) patients, as the dose of REQUIP is individually titrated to clinical therapeutic response and tolerability<span class="Italics">.</span> Pharmacokinetic trials conducted in patients demonstrated that oral clearance of ropinirole is reduced by 15% in patients older than 65Â years compared with younger patients <span class="Italics">[see</span><span class="Italics">Clinical Pharmacology (12.3)]</span>.</p>
<p>In clinical trials of extended-release ropinirole for Parkinsonâ€™s disease, 387Â patients were 65 years and older and 107Â patients were 75 years and older. Among patients receiving extended-release ropinirole, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span> was more common in elderly patients (10%) compared with non-elderly patients (2%). Theincidence of overall adverse reactions increased with increasing age for both patients receiving extended-release ropinirole and placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e0325cbf-53a6-4c5c-99d2-3294b80dc399"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment is necessary in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 30 to 50 mL/min). For patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis, a reduced maximum dose is recommended <span class="Italics">[see Dosage and Administration (2.2, 2.3), Clinical Pharmacology (12.3)]</span>. </p>
<p>The use of REQUIP in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30Â mL/min) without regular dialysis has not been studied. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c314d288-5f9c-4515-a1df-3bec7b77240a"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The pharmacokinetics of ropinirole have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_f2059788-5984-4ec1-ae0d-cb1b60484c73"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">The symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with REQUIP are generally related to its dopaminergic activity. General supportive measures are recommended. Vital signs should be maintained, if necessary. </p>
<p>In the Parkinsonâ€™s disease program, there have been patients who accidentally or intentionally took more than their prescribed dose of ropinirole. The largest <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> reported with ropinirole in clinical trials was 435Â mg taken over a 7-day period (62.1Â mg/day). Of patients who received a dose greater than 24Â mg/day, reported symptoms included adverse events commonly reported during dopaminergic therapy (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>), as well as <span class="product-label-link" type="condition" conceptid="4275889" conceptname="Visual hallucinations">visual hallucinations</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="4058397" conceptname="Claustrophobia">claustrophobia</span>, <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>. Additional symptoms reported for doses of 24Â mg or less or for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of unknown amount included <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, vasovagal <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_379ae4d1-afe7-4882-ace5-490043c9531b"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">REQUIP contains ropinirole, a non-ergoline dopamine agonist, as the hydrochloride salt. The chemical name of ropinirole hydrochloride is 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one and the empirical formula is C<span class="Sub">16</span>H<span class="Sub">24</span>N<span class="Sub">2</span>Oâ€¢HCl. The molecular weight is 296.84 (260.38 as the free base).</p>
<p>The structural formula is:</p>
<div class="Figure">
<a name="id32738295"></a><img alt="molecular structure.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de0bb94f-4fd8-4f27-5ba6-6f392dd5160f&amp;name=molecular%20structure.jpg">
</div>
<p>Ropinirole hydrochloride is a white to yellow solid with a melting range of 243Â° to 250Â°C and a solubility of 133Â mg/mL in water.</p>
<p>Each pentagonal film-coated TILTAB<span class="Sup">Â®</span> tablet with beveled edges contains 0.29 mg, 0.57Â mg, 1.14Â mg, 2.28 mg, 3.42 mg, 4.56 mg , or 5.70 mg ropinirole hydrochloride equivalent to ropinirole, 0.25Â mg, 0.5Â mg, 1Â mg, 2Â mg, 3Â mg, 4Â mg, or 5Â mg. Inactive ingredients consist of croscarmellose sodium, hydrous lactose, magnesium stearate, microcrystalline cellulose, and one or more of the following: carmine, FD&amp;C Blue No.Â 2 aluminum lake, FD&amp;C Yellow No.Â 6 aluminum lake, hypromellose, iron oxides, polyethylene glycol, polysorbate 80, titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_a64d950b-b289-4347-857a-e194054c391f"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_2d26c270-c480-4d5e-8a9e-e505fec00edd"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Ropinirole is a non-ergoline dopamine agonist. The precise mechanism of action of ropinirole as a treatment for Parkinsonâ€™s disease is unknown, although it is thought to be related to its ability to stimulate dopamine D<span class="Sub">2</span> receptors within the caudate-putamen in the brain. The precise mechanism of action of ropinirole as a treatment for <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> is unknown, although it is thought to be related to its ability to stimulate dopamine receptors.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_ba21d57c-5f22-4e11-a024-95ba7dee5079"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Clinical experience with dopamine agonists, including ropinirole, suggests an association with impaired ability to regulate blood pressure with resulting <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, especially during dose escalation. In some patients in clinical trials, blood pressure changes were associated with the emergence of orthostatic symptoms, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and, in one case in a healthy volunteer, transient <span class="product-label-link" type="condition" conceptid="4210313" conceptname="Sinus arrest">sinus arrest</span> with <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> <span class="Italics">[see Warnings and Precautions (5.2, 5.3)].</span></p>
<p>The mechanism of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> induced by ropinirole is presumed to be due to a D2-mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> is a common concomitant symptom of orthostatic signs and symptoms. </p>
<p>At oral doses as low as 0.2 mg, ropinirole suppressed serum prolactin concentrations in healthy male volunteers.</p>
<p>Ropinirole had no dose-related effect on ECG wave form and rhythm in young, healthy, male volunteers in the range of 0.01 to 2.5 mg.</p>
<p>Ropinirole had no dose- or exposure-related effect on mean QT intervals in healthy male and female volunteers titrated to doses up to 4 mg/day. The effect of ropinirole on QTc intervals at higher exposures achieved either due to drug interactions, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or at higher doses has not been systematically evaluated.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_682f7b93-886e-4890-b6ab-49c386db064f"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Ropinirole displayed linear kinetics over the dosing range of 1Â to 8Â mg three times daily. Steady-state concentrations are expected to be achieved within 2Â days of dosing. Accumulation upon multiple dosing is predictive from single dosing.</p>
<p><span class="Underline">Absorption</span></p>
<p>Ropinirole is rapidly absorbed after oral administration, reaching peak concentration in approximately 1 to 2 hours. In clinical trials, more than 88% of a radiolabeled dose was recovered in urine and the absolute bioavailability was 45% to 55%, indicating approximately 50% first-pass effect. </p>
<p>Relative bioavailability from a tablet compared with an oral solution is 85%. Food does not affect the extent of absorption of ropinirole, although its T<span class="Sub">max</span> is increased by 2.5Â hours and its C<span class="Sub">max </span>is decreased by approximately 25% when the drug is taken with a high-fat meal.</p>
<p><span class="Underline">Distribution</span></p>
<p>Ropinirole is widely distributed throughout the body, with an apparent volume of distribution of 7.5Â L/kg. It is up to 40% bound to plasma proteins and has a blood-to-plasma ratio of 1:1.</p>
<p><span class="Underline">Metabolism</span></p>
<p>Ropinirole is extensively metabolized by the liver. The major metabolic pathways are N-despropylation and hydroxylation to form the inactive N-despropyl metabolite and hydroxy metabolites. The N-despropyl metabolite is converted to carbamyl glucuronide, carboxylic acid, and N-despropyl hydroxy metabolites. The hydroxy metabolite of ropinirole is rapidly glucuronidated.</p>
<p>In vitro studies indicate that the major cytochrome P450 enzyme involved in the metabolism of ropinirole is CYP1A2, an enzyme known to be induced by smoking and omeprazole and inhibited by, for example, fluvoxamine, mexiletine, and the older fluoroquinolones such as ciprofloxacin and norfloxacin.</p>
<p><span class="Underline">Elimination</span></p>
<p>The clearance of ropinirole after oral administration is 47Â L/h and its elimination half-life is approximately 6Â hours. Less than 10% of the administered dose is excreted as unchanged drug in urine. N-despropyl ropinirole is the predominant metabolite found in urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%).</p>
<p><span class="Underline">Drug Interactions</span></p>
<p><span class="Italics">Digoxin:</span> Coadministration of REQUIP (2Â mg threeÂ times daily) with digoxin (0.125 to 0.25Â mg once daily) did not alter the steady-state pharmacokinetics of digoxin in 10Â patients.</p>
<p><span class="Italics">Theophylline: </span>Administration of theophylline (300Â mg twice daily, a substrate of CYP1A2) did not alter the steady-state pharmacokinetics of ropinirole (2Â mg threeÂ times daily) in 12Â patients with Parkinsonâ€™s disease. REQUIP (2Â mg three times daily) did not alter the pharmacokinetics of theophylline (5Â mg/kg IV) in 12Â patients with Parkinsonâ€™s disease.</p>
<p><span class="Italics">Ciprofloxacin:</span> Coadministration of ciprofloxacin (500 mg twice daily), an inhibitor of CYP1A2, with REQUIP (2 mg three times daily) increased ropinirole AUC by 84% on average and C<span class="Sub">max </span>by 60% (nÂ =Â 12 patients).</p>
<p><span class="Italics">Estrogens:</span> Population pharmacokinetic analysis revealed that estrogens (mainly ethinylestradiol: intake 0.6 to 3 mg over 4-month to 23-year period) reduced the oral clearance of ropinirole by 36% in 16 patients.</p>
<p><span class="Italics">L-dopa:</span> Coadministration of carbidopa + L-dopa (10/100Â mg twice daily) with REQUIP (2Â mg three times daily) had no effect on the steady-state pharmacokinetics of ropinirole (nÂ =Â 28 patients). Oral administration of REQUIP 2Â mg three times daily increased mean steady-state C<span class="Sub">max</span> of L-dopa by 20%, but its AUC was unaffected (nÂ =Â 23 patients).</p>
<p><span class="Italics">Commonly Administered Drugs: </span>Population analysis showed that commonly administered drugs, e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, and anticholinergics, did not affect the clearance of ropinirole. An in vitro study indicates that ropinirole is not a substrate for P-gp. Ropinirole and its circulating metabolites do not inhibit or induce P450 enzymes; therefore, ropinirole is unlikely to affect the pharmacokinetics of other drugs by a P450 mechanism.</p>
<p><span class="Underline">Specific Populations</span></p>
<p>Because therapy with REQUIP is initiated at a low dose and gradually titrated upward according to clinical tolerability to obtain the optimum therapeutic effect, adjustment of the initial dose based on gender, weight, or age is not necessary.</p>
<p><span class="Italics">Age:</span> Oral clearance of ropinirole is reduced by 15% in patients older than 65 years compared with younger patients. Dosage adjustment is not necessary in the elderly (older than 65Â years), as the dose of ropinirole is to be individually titrated to clinical response.</p>
<p><span class="Italics">Gender:</span> Female and male patients showed similar clearance.</p>
<p><span class="Italics">Race:</span>The influence of race on the pharmacokinetics of ropinirole has not been evaluated.</p>
<p><span class="Italics">Cigarette Smoking:<span class="Bold"></span></span>Smoking is expected to increase the clearance of ropinirole since CYP1A2 is known to be induced by smoking. In a trial in patients with RLS, smokers (nÂ =Â 7) had an approximately 30% lower C<span class="Sub">max</span> and a 38% lower AUC than did <span class="product-label-link" type="condition" conceptid="4222303" conceptname="Non-smoker">nonsmokers</span> (nÂ =Â 11) when those parameters were normalized for dose.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> Based on population pharmacokinetic analysis, no difference was observed in the pharmacokinetics of ropinirole in subjects with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance between 30 to 50Â mL/min) compared with an age-matched population with creatinine clearance above 50Â mL/min. Therefore, no dosage adjustment is necessary in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>A trial of ropinirole in subjects with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on hemodialysis has shown that clearance of ropinirole was reduced by approximately 30%. The recommended maximum dose should be lower in these patients <span class="Italics">[see Dosage and Administration (2.2, 2.3)]</span>.</p>
<p>The use of ropinirole in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30Â mL/min) without regular dialysis has not been studied.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> The pharmacokinetics of ropinirole have not been studied in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Because ropinirole is extensively metabolized by the liver, these patients may have higher plasma levels and lower clearance of ropinirole than patients with normal hepatic function. </p>
<p><span class="Italics">Other Diseases:</span> Population pharmacokinetic analysis revealed no change in the clearance of ropinirole in patients with concomitant diseases such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>/<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> compared with patients with Parkinsonâ€™s disease only.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_8dce28d4-b573-4c86-8877-df12d019cda8"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_34a8e19f-c27b-4803-a354-85b5b90365f6"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis</span></p>
<p>Two-year carcinogenicity studies of ropinirole were conducted in mice at oral doses of 5, 15, and 50Â mg/kg/day and in rats at oral doses of 1.5, 15, and 50Â mg/kg/day.</p>
<p>In rats, there was an increase in testicular Leydig cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> at all doses tested. The lowest dose tested (1.5Â mg/kg/day) is less than the MRHD for Parkinsonâ€™s disease (24 mg/day) on a mg/m2 basis. The endocrine mechanisms believed to be involved in the production of these tumors in rats are not considered relevant to humans. </p>
<p>In mice, there was an increase in benign uterine endometrial <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> at a dose of 50Â mg/kg/day. The highest dose not associated with this finding (15 mg/kg/day) is three times the MRHD on a mg/m2 basis. </p>
<p><span class="Underline">Mutagenesis</span></p>
<p>Ropinirole was not mutagenic or clastogenic in in vitro (Ames, chromosomal aberration in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> tk) assays or in the in vivo mouse micronucleus test. </p>
<p><span class="Underline">Impairment of Fertility</span></p>
<p>When administered to female rats prior to and during mating and throughout pregnancy, ropinirole caused disruption of implantation at oral doses of 20Â mg/kg/day (8Â times the MRHD on a mg/m<span class="Sup">2</span> basis) or greater. This effect in rats is thought to be due to the prolactin-lowering effect of ropinirole. In rat studies using a low oral dose (5Â mg/kg) during the prolactin-dependent phase of early pregnancy (gestation days 0 to 8), ropinirole did not affect female fertility at oral doses up to 100Â mg/kg/day (40Â times the MRHD on a mg/m<span class="Sup">2</span> basis). No effect on male fertility was observed in rats at oral doses up to 125Â mg/kg/day (50Â times the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_de96d605-45cc-4e59-9325-85a8f8821f9e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_27591e1f-7fb2-4397-b3f9-dd9756fc774d"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Parkinsonâ€™s Disease </h2>
<p class="First">The effectiveness of REQUIP in the treatment of Parkinsonâ€™s disease was evaluated in a multinational drug development program consisting of 11Â randomized, controlled trials. Four trials were conducted in patients with early Parkinsonâ€™s disease and no concomitant levodopa (L-dopa) and seven trials were conducted in patients with advanced Parkinsonâ€™s disease with concomitant L-dopa.</p>
<p>Three placeboâ€‘controlled trials provide evidence of effectiveness of REQUIP in the management of patients with Parkinsonâ€™s disease who were and were not receiving concomitant L-dopa. Two of these three trials enrolled patients with early Parkinsonâ€™s disease (without L-dopa) and one enrolled patients receiving L-dopa.</p>
<p>In these trials a variety of measures were used to assess the effects of treatment (e.g., the Unified Parkinsonâ€™s Disease Rating Scale [UPDRS], Clinical Global Impression [CGI] scores, patient diaries recording time â€œonâ€? and â€œoff,â€? tolerability of L-dopa dose reductions).</p>
<p>In both trials of patients with early Parkinsonâ€™s disease (without L-dopa), the motor component (Part III) of the UPDRS was the primary outcome assessment. The UPDRS is a multi-item rating scale intended to evaluate mentation (Part I), activities of daily living (Part II), motor performance (Part III), and complications of therapy (Part IV). Part III of the UPDRS contains 14 items designed to assess the severity of the cardinal motor findings in patients with Parkinsonâ€™s disease (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, postural instability) scored for different body regions and has a maximum (worst) score of 108. In the trial of patients with advanced Parkinsonâ€™s disease (with L-dopa), both reduction in percent awake time spent â€œoffâ€? and the ability to reduce the daily use of L-dopa were assessed as a combined endpoint and individually.</p>
<p><span class="Underline">Trials in Patients with Early Parkinsonâ€™s Disease (without L-dopa)</span></p>
<p>Trial 1 was a 12-week multicenter trial in which 63 patients with idiopathic Parkinsonâ€™s disease receiving concomitant anti-Parkinson medication (but not L-dopa) were enrolled and 41 were randomized to REQUIP and 22 to placebo. Patients had a mean disease duration of approximately 2Â years. Patients were eligible for enrollment if they presented with <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span> and at least <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">rigidity</span>, or postural instability. In addition, they must have been classified as Hoehn &amp; Yahr Stage I-IV. This scale, ranging from IÂ =Â unilateral involvement with minimal impairment to VÂ =Â confined to wheelchair or bed, is a standard instrument used for staging patients with Parkinsonâ€™s disease. The primary outcome measure in this trial was the proportion of patients experiencing a decrease (compared with baseline) of at least 30% in the UPDRS motor score.</p>
<p>Patients were titrated for up to 10Â weeks, starting at 0.5Â mg twice daily, with weekly increments of 0.5Â mg twice daily to a maximum of 5Â mg twice daily. Once patients reached their maximally tolerated dose (or 5Â mg twice daily), they were maintained on that dose through 12Â weeks. The mean dose achieved by patients at trial endpoint was 7.4Â mg/day. Mean baseline UPDRS motor score was 18.6 for patients treated with REQUIP and 19.9 for patients treated with placebo. At the end of 12Â weeks, the percentage of responders was greater on REQUIP than on placebo and the difference was statistically significant (Table 6). </p>
<table width="100%">
<caption><span>Table 6. Percent Responders for UPDRS Motor Score in Trial 1 (Intent-to-Treat Population)</span></caption>
<col width="24%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">% Responders</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Difference from Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">41%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">REQUIP</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">71%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">30%</p></td>
</tr>
</tbody>
</table>
<p>Trial 2 in patients with early Parkinsonâ€™s disease (without L-dopa) was a doubleâ€‘blind, randomized, placebo-controlled, 6-month trial. In this trial, 241 patients were enrolled and 116 were randomized to REQUIP and 125 to placebo. Patients were essentially similar to those in the trial described above; concomitant use of selegiline was allowed, but patients were not permitted to use anticholinergics or amantadine during the trial. Patients had a mean disease duration of 2Â years and limited (not more than a 6-week period) or no prior exposure to L-dopa. The starting dosage of REQUIP in this trial was 0.25Â mg threeÂ times daily. The dosage was titrated at weekly intervals by increments of 0.25Â mg threeÂ times daily to a dosage of 1Â mg threeÂ times daily. Further titrations at weekly intervals were at increments of 0.5Â mg threeÂ times daily up to a dosage of 3Â mg threeÂ times daily, and then weekly at increments of 1Â mg threeÂ times daily. Patients were to be titrated to a dosage of at least 1.5Â mg threeÂ times daily and then to their maximally tolerated dosage, up to a maximum of 8Â mg threeÂ times daily. The mean dose attained in patients at trial endpoint was 15.7Â mg/day. </p>
<p>The primary measure of effectiveness was the mean percent reduction (improvement) from baseline in the UPDRS motor score. At the end of the 6-month trial, patients treated with REQUIP showed improvement in motor score compared with placebo and the difference was statistically significant (Table 7).</p>
<table width="100%">
<caption><span>Table 7. Mean Percentage Change from Baseline in UPDRS Motor Score at End of Treatment in Trial 2 (Intent-to-Treat Population)</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
<p class="First"><span class="Bold">Baseline UPDRS</span></p>
<p><span class="Bold">Motor Score</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Mean Change from Baseline</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Difference from Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">+4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">REQUIP</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17.9</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-22%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-26%</p></td>
</tr>
</tbody>
</table>
<p><span class="Underline">Trial in Patients with Advanced Parkinsonâ€™s Disease (with L-dopa)</span></p>
<p>Trial 3 was a double-blind, randomized, placebo-controlled, 6-month trial that randomized 149Â patients (Hoehn &amp; Yahr IIâ€‘IV) who were not adequately controlled on L-dopa. Ninety-five patients were randomized to REQUIP and 54 were randomized to placebo. Patients in this trial had a mean disease duration of approximately 9Â years, had been exposed to L-dopa for approximately 7Â years, and had experienced â€œon-offâ€? periods with L-dopa therapy. Patients previously receiving stable doses of selegiline, amantadine, and/or anticholinergic agents could continue on these agents during the trial. Patients were started at a dosage of 0.25Â mg threeÂ times daily of REQUIP and titrated upward by weekly intervals until an optimal therapeutic response was achieved. The maximum dosage of trial medication was 8Â mg threeÂ times daily. All patients had to be titrated to at least a dosage of 2.5Â mg threeÂ times daily. Patients could then be maintained on this dosage level or higher for the remainder of the trial. Once a dosage of 2.5Â mg threeÂ times daily was achieved, patients underwent a mandatory reduction in their L-dopa dosage, to be followed by additional mandatory reductions with continued escalation of the dosage of REQUIP. Reductions in the dosage of l-dopa were also allowed if patients experienced adverse reactions that the investigator considered related to dopaminergic therapy. The mean dose attained at trial endpoint was 16.3Â mg/day. The primary outcome was the proportion of responders, defined as patients who were able both to achieve a decrease (compared with baseline) of at least 20% in their L-dopa dosage and a decrease of at least 20% in the proportion of the time awake in the â€œoffâ€? condition (a period of time during the day when patients are particularly immobile), as determined by subject diary. In addition, the mean change in â€œoffâ€? time from baseline and the percent change from baseline in daily L-dopa dosage were examined.</p>
<p>At the end of 6Â months, the percentage of responders was greater on REQUIP than on placebo and the difference was statistically significant (Table 8).</p>
<p>Based on the protocol-mandated reductions in L-dopa dosage with escalating doses of REQUIP, patients treated with REQUIP had a 19.4% mean reduction in L-dopa dosage while patients treated with placebo had a 3% reduction. Mean daily L-dopa dosage at baseline was 759 mg for patients treated with REQUIP and 843 mg for patients treated with placebo. </p>
<p>The mean number of daily â€œoffâ€? hours at baseline was 6.4Â hours for patients treated with REQUIP and 7.3Â hours for patients treated with placebo. At the end of the 6-month trial, there was a mean reduction of 1.5 hours of â€œoffâ€? time in patients treated with REQUIP and a mean reduction of 0.9 hours of â€œoffâ€? time in patients treated with placebo, resulting in a treatment difference of 0.6 hours of â€œoffâ€? time.</p>
<table width="100%">
<caption><span>Table 8. Mean Responder Percentage of Patients Reducing Daily L-Dopa Dosage by at Least 20% and Daily Proportion of â€œOffâ€? Time by at Least 20% at End of Treatment in Trial 3 (Intent-to-Treat Population)</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Treatment</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">% Responders</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Difference from Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Placebo</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">11%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">NA</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><p class="First">REQUIP</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">28%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">17%</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e7283ced-bf18-4068-9cbc-b4505e2869bc"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span></h2>
<p class="First">The effectiveness of REQUIP in the treatment of RLS was demonstrated in randomized, double-blind, placebo-controlled trials in adults diagnosed with RLS using the International <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> Study Group diagnostic criteria. Patients were required to have a history of a minimum of 15Â RLS episodes/month during the previous month and a total score of â‰¥15 on the International RLS Rating Scale (IRLS scale) at baseline. Patients with RLS secondary to other conditions (e.g., pregnancy, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>) were excluded. All trials employed flexible dosing, with patients initiating therapy at 0.25Â mg REQUIP once daily. Patients were titrated based on clinical response and tolerability over 7Â weeks to a maximum of 4Â mg once daily. All doses were taken between 1 and 3Â hours before bedtime.</p>
<p>A variety of measures were used to assess the effects of treatment, including the IRLS scale and Clinical Global Impression-Global Improvement (CGI-I) scores. The IRLS scale contains 10Â items designed to assess the severity of sensory and motor symptoms, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbance</span>, daytime <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and impact on activities of daily living and mood associated with RLS. The range of scores is 0 to 40, with 0 being absence of RLS symptoms and 40 the most severe symptoms. Three of the controlled trials utilized the change from baseline in the IRLS scale at the Week 12 endpoint as the primary efficacy outcome.</p>
<p>Three hundred eighty patients were randomized to receive REQUIP (nÂ =Â 187) or placebo (nÂ =Â 193) in a US trial (RLS-1); 284 were randomized to receive either REQUIP (nÂ =Â 146) or placebo (nÂ =Â 138) in a multinational trial (excluding US) (RLS-2); and 267 patients were randomized to REQUIP (nÂ =Â 131) or placebo (nÂ =Â 136) in a multinational trial (including US) (RLS-3). Across the three trials, the mean duration of RLS was 16 to 22Â years (range: 0 to 65Â years), mean age was approximately 54Â years (range: 18 to 79Â years), and approximately 61% were women. The mean dose at Week 12 was approximately 2Â mg/day for the three trials.</p>
<p>At baseline, mean total IRLS score was 22.0 for REQUIP and 21.6 for placebo in RLS-1, was 24.4 for REQUIP and 25.2 for placebo in RLS-2, and was 23.6 for REQUIP and 24.8 for placebo in RLS-3. In all three trials, a statistically significant difference between the treatment group receiving REQUIP and the treatment group receiving placebo was observed at Week 12 for both the mean change from baseline in the IRLS scale total score and the percentage of patients rated as responders (much improved or very much improved) on the CGI-I (see Table 9). </p>
<table width="100%">
<caption><span>Table 9. Mean Change in Total IRLS Score and Percent Responders on CGI-I</span></caption>
<col width="44%">
<col width="18%">
<col width="18%">
<col width="18%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="bottom"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">REQUIP</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First"><span class="Bold">Difference from Placebo</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Mean change in total IRLS score at Week 12</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>RLS-1 </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-13.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-9.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-3.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>RLS-2</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-11.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-8.0</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-3.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>RLS-3 </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-11.2</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-8.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">-2.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Percent responders on CGI-I at Week 12</p></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>RLS-1</dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">73.3%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">56.5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">16.8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><dl>
<dt>Â </dt>
<dd>RLS-2 </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">53.4%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">40.9%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">12.5%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>RLS-3 </dd>
</dl></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">59.5%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">39.6%</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">19.9%</p></td>
</tr>
</tbody>
</table>
<p>Long-term maintenance of efficacy in the treatment of RLS was demonstrated in a 36â€‘week trial. Following a 24-week, single-blind treatment phase (flexible dosages of REQUIP of 0.25 to 4Â mg once daily), patients who were responders (defined as a decrease of &gt;6 points on the IRLS scale total score relative to baseline) were randomized in double-blind fashion to placebo or continuation of REQUIP for an additional 12Â weeks. Relapse was defined as an increase of at least 6 points on the IRLS scale total score to a total score of at least 15, or withdrawal due to lack of efficacy. For patients who were responders at Week 24, the mean dose of REQUIP was 2Â mg (range: 0.25 to 4 mg).<span class="Italics"></span>Patientscontinued on REQUIP demonstrated a significantly lower relapse rate compared with patients randomized to placebo (32.6% versus 57.8%, <span class="Italics">P</span> = 0.0156).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_e3c24fe0-7509-4ec9-84eb-33d0aef836f2"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each pentagonal film-coated TILTABÂ® tablet with beveled edges contains ropinirole hydrochloride equivalent to the labeled amount of ropinirole as follows:</p>
<dl>
<dt>â€¢</dt>
<dd>0.25Â mg: white tablets imprinted with â€œSBâ€? and â€œ4890â€? in bottles of 100 (NDC 0007-4890-20)</dd>
<dt>â€¢</dt>
<dd>0.5Â mg: yellow tablets imprinted with â€œSBâ€? and â€œ4891â€? in bottles of 100 (NDC 0007-4891-20)</dd>
<dt>â€¢</dt>
<dd>1 mg: green tablets imprinted with â€œSBâ€? and â€œ4892â€? in bottles of 100 (NDC 0007-4892-20)</dd>
<dt>â€¢</dt>
<dd>2Â mg: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellowish-pink tablets imprinted with â€œSBâ€? and â€œ4893â€? in bottles of 100 (NDC 0007-4893-20) </dd>
<dt>â€¢</dt>
<dd>3Â mg: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> to moderate reddish-purple tablets, imprinted with â€œSBâ€? and â€œ4895â€? in bottles of 100 (NDC 0007-4895-20)</dd>
<dt>â€¢</dt>
<dd>4Â mg: <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> brown tablets imprinted with â€œSBâ€? and â€œ4896â€? in bottles of 100 (NDC 0007-4896-20) </dd>
<dt>â€¢</dt>
<dd>5Â mg: blue tablets imprinted with â€œSBâ€? and â€œ4894â€? in bottles of 100 (NDC 0007-4894-20)</dd>
</dl>
<p><span class="Underline">Storage</span></p>
<p>Store at controlled room temperature 20Â° - 25Â°C (68Â° - 77Â°F) [see USP]. Protect from light and moisture. Close container tightly after each use.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_b9896ba1-4b75-4eda-a367-5178189fc7bb"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise the patient to read the FDA-approved patient labeling (Patient Information).</p>
<p><span class="Underline">Dosing Instructions</span></p>
<p>Instruct patients to take REQUIP only as prescribed. If a dose is missed, advise patients not to double their next dose. REQUIP can be taken with or without food <span class="Italics">[see Dosage and Administration (2.1)]</span>.</p>
<p>Ropinirole is the active ingredient in both REQUIPÂ XL and REQUIP tablets (the immediateâ€‘release formulation). Ask your patients if they are taking another medication containing ropinirole.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Advise patients about the potential for developing a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> including manifestations such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> when taking any ropinirole product. Inform patients who experience these or similar reactions to immediately contact their healthcare professional <span class="Italics">[see Contraindications (4)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> Asleep during Activities of Daily Living and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></span></p>
<p>Alert patients to the potential sedating effects caused by REQUIP, including <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and the possibility of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while engaged in activities of daily living. Because <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> is a frequent adverse reaction with potentially serious consequences, patients should not drive a car, operate machinery, or engage in other potentially dangerous activities until they have gained sufficient experience with REQUIP to gauge whether or not it affects their mental and/or motor performance adversely. Advise patients that if increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> or episodes of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep during activities of daily living (e.g., conversations, eating, driving a motor vehicle, etc.) are experienced at any time during treatment, they should not drive or participate in potentially dangerous activities until they have contacted their physician.</p>
<p>Advise patients of possible additive effects when patients are taking other sedating medications, alcohol, or other central nervous system depressants (e.g., benzodiazepines, antipsychotics, antidepressants, etc.) in combination with REQUIP or when taking a concomitant medication (e.g., ciprofloxacin) that increases plasma levels of ropinirole <span class="Italics">[see Warnings and Precautions (5.1)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic Hypotension</span></span></p>
<p>Advise patients that they may experience <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> and may develop <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with or without symptoms such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, and sometimes <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> while taking REQUIP, especially if they are elderly. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> and/or orthostatic symptoms may occur more frequently during initial therapy or with an increase in dose at any time (cases have been seen after weeks of treatment).<span class="Italics"></span>Postural/orthostatic symptoms may be related to sitting up or standing. Accordingly, caution patients against standing rapidly after sitting or lying down, especially if they have been doing so for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> and especially at the initiation of treatment with REQUIP <span class="Italics">[see Warnings and Precautions (5.2, 5.3)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>/<span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic</span>-like Behavior</span></p>
<p>Inform patients that they may experience <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (unreal visions, sounds, or sensations), and that other <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior can occur while taking REQUIP. The elderly are at greater risk than younger patients with Parkinsonâ€™s disease. This risk is greater in patients who are taking REQUIP with L-dopa or taking higher doses of REQUIP and may also be further increased in patients taking any other drugs that increase dopaminergic tone. Tell patients to report <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior to their healthcare provider promptly should they develop <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">Dyskinesia</span></span></p>
<p>Inform patients that REQUIP may cause and/or exacerbate pre-existing <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesias</span> <span class="Italics">[see Warnings and Precautions (5.5)]</span>.</p>
<p><span class="Underline">Impulse Control/Compulsive Behaviors</span></p>
<p>Advise patients that they may experience impulse control and/or compulsive behaviors while taking one or more of the medications (including REQUIP) that increase central dopaminergic tone, that are generally used for the treatment of Parkinsonâ€™s disease. Advise patients to inform their physician or healthcare provider if they develop new or increased <span class="product-label-link" type="condition" conceptid="4023166" conceptname="Gambling">gambling</span> urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while being treated with REQUIP. Physicians should consider dose reduction or stopping the medication if a patient develops such urges while taking REQUIP <span class="Italics">[see Warnings and Precautions (5.6)]</span>.</p>
<p><span class="Underline">Withdrawal-emergent <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></span></p>
<p>Advise patients to contact their healthcare provider if they wish to discontinue REQUIP or decrease the dose of REQUIP <span class="Italics">[see Warnings and Precautions (5.7)]</span>.</p>
<p><span class="Underline">Melanoma</span></p>
<p>Advise patients with Parkinsonâ€™s disease that they have a higher risk of developing melanoma. Advise patients to have their skin examined on a regular basis by a qualified healthcare provider (e.g., dermatologist) when using REQUIP for any indication <span class="Italics">[see Warnings and Precautions (5.8)]</span>.</p>
<p><span class="Underline">Augmentation and Rebound</span></p>
<p>Inform patients with RLS that augmentation and/or rebound may occur after starting treatment with REQUIP <span class="Italics">[see Warnings and Precautions (5.9)]</span>. </p>
<p><span class="Underline">Nursing Mothers</span></p>
<p>Because of the possibility that ropinirole may be excreted in breast milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother <span class="Italics">[see Use in Specific Populations (8.3)]</span>. Advise patients that REQUIP could inhibit lactation because ropinirole inhibits prolactin secretion<span class="Italics">.</span></p>
<p><span class="Underline">Pregnancy</span></p>
<p>Because ropinirole has been shown to have adverse effects on embryo-fetal development, including teratogenic effects, in animals, and because experience in humans is limited, advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy <span class="Italics">[see Use in Specific Populations (8.1)]</span>. </p>
<p>REQUIP and TILTAB are registered trademarks of the GSK group of companies.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Â©2014, the GSK group of companies. All rights reserved.</p>
<p>REP:4PI</p>
<p>PHARMACISTâ€”DETACH HERE AND GIVE INSTRUCTIONSTO PATIENT</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_149531e1-8cf9-4623-88d7-ac18c9f1d9b6"></a><a name="section-16"></a><p></p>
<p class="First">Patient Information</p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span> (RE-qwip)</span></p>
<p><span class="Bold">(ropinirole)</span></p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Bold">REQUIP XL<span class="Sup">Â® </span>(RE-qwip)</span></p>
<p><span class="Bold">(ropinirole)</span></p>
<p><span class="Bold">Extended-release Tablets</span></p>
<p><span class="Bold">If you have Parkinsonâ€™s disease, read this side.</span></p>
<p><span class="Bold">If you have <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS), read the other side.</span></p>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><dl>
<dt>Â </dt>
<dd>
<span class="Bold">Important Note: </span>REQUIP XL has not been studied in <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS) and is not approved for the treatment of RLS. However, an immediate-release form of ropinirole (REQUIP) is approved for the treatment of moderate to severe primary RLS (see other side of this leaflet).</dd>
</dl></td></tr></tbody>
</table>
<p>Read this information completely before you start taking REQUIP or REQUIP XL. Read the information each time you get more medicine. There may be new information. This leaflet provides a summary about REQUIP and REQUIP XL. It does not include everything there is to know about your medicine. This information should not take the place of discussions with your healthcare provider about your medical condition or treatment with REQUIP or REQUIP XL.</p>
<p><span class="Bold">What is the most important information I should know about REQUIP and REQUIP XL?</span></p>
<p><span class="Bold">REQUIP and REQUIP XL can cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span>You may experience a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> characterized by <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and/or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, mouth, tongue, or throat, which may cause problems in swallowing or breathing. <span class="Bold">If you experience any of these reactions</span>, you should not take REQUIP or REQUIP XL again until you talk to a healthcare provider and seek their advice.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> asleep during normal activities.</span> You may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep while doing normal activities such as driving a car, doing physical tasks, or using hazardous machinery while taking REQUIP or REQUIP XL. You may suddenly <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep without being drowsy or without warning. This may result in having <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>. Your chances of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while doing normal activities while taking REQUIP or REQUIP XL are greater if you take other medicines that cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Tell your healthcare provider right away if this happens. Before starting REQUIP or REQUIP XL, be sure to tell your healthcare provider if you take any medicines that make you drowsy. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Fainting</span>.</span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Fainting</span> can happen, and sometimes your heart rate may be decreased. This can happen especially when you start taking REQUIP or REQUIP XL or your dose is increased. Tell your healthcare provider if youfaint or feel dizzy or light-headed.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Decrease in blood pressure.</span> REQUIP and REQUIP XL can decrease your blood pressure. Decreases in your blood pressure (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) can happen, especially when you start taking REQUIP or REQUIP XL or when your dose is changed. If you <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or feel dizzy, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nauseated</span>, or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweaty</span> when you stand up from sitting or lying down (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>), this may mean that your blood pressure is decreased. When you change position from lying down or sitting to standing up, you should do it carefully and slowly. Call your healthcare provider if you have any of the symptoms of decreased blood pressure listed above. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Increase in blood pressure. </span>REQUIP XL may increase your blood pressure. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in heart rate (decrease or increase).</span> REQUIP and REQUIP XL can decrease or increase your heart rate. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> and other <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior.</span> REQUIP and REQUIP XL can cause or worsen <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like behavior including <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are not real), <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, excessive suspicion, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, delusional beliefs (believing things that are not real), and disorganized thinking. The chances of having <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> or these other <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like changes are higher in people with Parkinsonâ€™s disease who are taking REQUIP or REQUIP XL or taking higher doses of these drugs. If you have <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> or any of these other <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span>-like changes, talk with your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Uncontrolled sudden movements.</span> REQUIP and REQUIP XL may cause uncontrolled sudden movements or make such movements you already have worse or more frequent. Tell your healthcare provider if this happens. The doses of your anti-Parkinsonâ€™s medicine may need to be changed. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Unusual urges.</span> Some patients taking REQUIP or REQUIP XL get urges to behave in a way unusual for them. Examples of this are an unusual urge to gamble, increased sexual urges and behaviors, or an uncontrollable urge to shop, spend money, or eat. If you notice or your family notices that you are developing any unusual behaviors, talk to your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Increased chance of skin cancer (melanoma).</span> People with Parkinsonâ€™s disease may have a higher chance of getting melanoma. It is not known if REQUIP and REQUIP XL increase your chances of getting melanoma. You and your healthcare provider should check your skin on a regular basis. Tell your healthcare provider right away if you notice any changes in your skin such as a change in the size, shape, or color of moles on your skin. </dd>
</dl>
<p><span class="Bold">What are REQUIP and REQUIP XL?</span></p>
<dl>
<dt>â€¢</dt>
<dd>REQUIP is a short-acting prescription medicine containing ropinirole (usually taken 3 times a day) that is used to treat Parkinsonâ€™s disease. It is also used to treat a condition called <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS). </dd>
<dt>â€¢</dt>
<dd>REQUIP XL is a long-acting prescription medicine containing ropinirole (taken 1 time a day) that is used only to treat Parkinsonâ€™s disease but not to treat RLS.</dd>
</dl>
<p>Having one of these conditions does not mean you have or will develop the other condition.</p>
<p>You should not be taking more than 1 medicine containing ropinirole. Tell your healthcare provider if you are taking any other medicine containing ropinirole.</p>
<p>It is not known if REQUIP and REQUIP XL are safe and effective for use in children younger than 18 years of age.</p>
<p><span class="Bold">Who should not take REQUIP or REQUIP XL?</span></p>
<p><span class="Bold">Do not take REQUIP or REQUIP XL if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>are allergic to ropinirole or any of the ingredients in REQUIP or REQUIP XL. See the end of this page for a complete list of the ingredients in REQUIP and REQUIP XL. </dd>
</dl>
<p><span class="Bold">Call your healthcare provider and get help right away if you have any of the following symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, mouth, tongue, or throat</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></span></dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking REQUIP or REQUIP XL?</span></p>
<p><span class="Bold">Before you take REQUIP or REQUIP XL, tell your healthcare provider if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">daytime sleepiness</span> from a <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span> or have unexpected or unpredictable <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or periods of sleep.</dd>
<dt>â€¢</dt>
<dd>are taking any other prescription or over-the-counter medicines. Some of these medicines may increase your chances of getting side effects while taking REQUIP or REQUIP XL.</dd>
<dt>â€¢</dt>
<dd>start or stop taking other medicines while you are taking REQUIP or REQUIP XL. This may increase your chances of getting side effects.</dd>
<dt>â€¢</dt>
<dd>start or stop smoking while you are taking REQUIP or REQUIP XL. Smoking may decrease the treatment effect of REQUIP or REQUIP XL.</dd>
<dt>â€¢</dt>
<dd>feel dizzy, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nauseated</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweaty</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> when you stand up from sitting or lying down.</dd>
<dt>â€¢</dt>
<dd>drink alcoholic beverages. This may increase your chances of becoming drowsy or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> while taking REQUIP or REQUIP XL.</dd>
<dt>â€¢</dt>
<dd>have high or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>.</dd>
<dt>â€¢</dt>
<dd>have or have had heart problems.</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. REQUIP and REQUIP XL should only be used during pregnancy if needed.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding. It is not known if REQUIP or REQUIP XL passes into your breast milk. Talk to your healthcare provider to decide whether you will breastfeed or take REQUIP or REQUIP XL.</dd>
<dt>â€¢</dt>
<dd>have any other medical conditions.</dd>
</dl>
<p><span class="Bold">How should I take REQUIP or REQUIP XL for Parkinsonâ€™s disease?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take REQUIP or REQUIP XL<span class="Bold"></span>exactly as directed by your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not</span> suddenly stop taking REQUIP or REQUIP XL without talking to your healthcare provider. If you stop this medicine suddenly, you may develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or severe <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle stiffness</span>.</dd>
<dt>â€¢</dt>
<dd>Before starting REQUIP or REQUIP XL, you should talk to your healthcare provider about what to do if you miss a dose. If you have missed the previous dose and it is time for your next dose, <span class="Bold">do not double the dose.</span>
</dd>
<dt>â€¢</dt>
<dd>Your healthcare provider will start you on a low dose of REQUIP or REQUIP XL. Your healthcare provider will change the dose until you are taking the right amount of medicine to control your symptoms. <span class="Bold">It may take several weeks before you reach a dose that controls your symptoms.</span>
</dd>
</dl>
<p><span class="Bold">If you are taking REQUIP:</span></p>
<dl>
<dt>â€¢</dt>
<dd>REQUIP Tablets are usually taken 3 times a day for Parkinsonâ€™s disease.</dd>
</dl>
<p><span class="Bold">If you are taking REQUIP XL:</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take REQUIP XL<span class="Bold"></span>Extended-Release Tablets 1 time each day for Parkinsonâ€™s disease, preferably at or around the same time of day.</dd>
<dt>â€¢</dt>
<dd>Swallow<span class="Bold"></span>REQUIP XL Extended-Release Tablets whole. Do not chew, crush, or split REQUIP XL Extended-Release Tablets.</dd>
<dt>â€¢</dt>
<dd>REQUIP XL Extended-Release Tablets release drug over a 24-hour period. If you have a condition where medicine passes through your body too quickly, such as <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, the tablet(s) may not dissolve completely and you may see tablet residue in your stool. If this happens, let your healthcare provider know as soon as possible. </dd>
</dl>
<p><span class="Bold">If you are taking either REQUIP or REQUIP XL:</span></p>
<dl>
<dt>â€¢</dt>
<dd>Contact your healthcare provider if you stop taking REQUIP or REQUIP XL for any reason. Do not restart without talking with your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>Your healthcare provider may prescribe REQUIP or REQUIP XL alone, or add REQUIP or REQUIP XL to medicine that you are already taking for Parkinsonâ€™s disease.</dd>
<dt>â€¢</dt>
<dd>You should not substitute REQUIP for REQUIP XL, or REQUIP XL for REQUIP without talking with your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>You can take REQUIP or REQUIP XL with or without food. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of REQUIP and REQUIP XL?</span></p>
<p><span class="Bold">REQUIP and REQUIP XL can cause serious side effects, including: </span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">See â€œWhat is the most important information I should know about REQUIP and REQUIP XL?â€?</span></dd>
</dl>
<p>The most common side effects of REQUIP and REQUIP XL include:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (seeing or hearing things that are not real)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd>uncontrolled sudden movements</dd>
<dt>â€¢</dt>
<dd>leg <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></dd>
<dt>â€¢</dt>
<dd>increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or does not go away.</p>
<p>This is not a complete list of side effects and should not take the place of talking with your healthcare provider. Your healthcare provider or pharmacist can give you a more complete list of possible side effects.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store REQUIP and REQUIP XL?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store REQUIP or REQUIP XL at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</dd>
<dt>â€¢</dt>
<dd>Keep REQUIP or REQUIP XL in a tightly closed container and out of direct sunlight.</dd>
</dl>
<p><span class="Bold">Keep REQUIP or REQUIP XL and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of REQUIP and REQUIP XL.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not take REQUIP or REQUIP XL for a condition for which it was not prescribed. Do not give REQUIP or REQUIP XL to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This side of the patient information leaflet summarizes the most important information about REQUIP and REQUIP XL for Parkinsonâ€™s disease. If you would like more information, talk with your healthcare provider or pharmacist. You can ask your healthcare provider or pharmacist for information about REQUIP and REQUIP XL that is written for healthcare professionals. For more information go to www.gsk.com or call 1-888-825-5249 (toll-free).</p>
<p><span class="Bold">What are the ingredients in REQUIP and REQUIP XL?</span></p>
<p><span class="Bold">The following ingredients are in REQUIP:</span></p>
<p><span class="Bold">Active ingredient:</span> ropinirole (as ropinirole hydrochloride)</p>
<p><span class="Bold">Inactive ingredients:</span> croscarmellose sodium, hydrous lactose, magnesium stearate, microcrystalline cellulose, and one or more of the following: carmine, FD&amp;C Blue No. 2 aluminum lake, FD&amp;C Yellow No. 6 aluminum lake, hypromellose, iron oxides, polyethylene glycol, polysorbate 80, titanium dioxide.</p>
<p><span class="Bold">The following ingredients are in REQUIP XL:</span></p>
<p><span class="Bold">Active ingredient:</span> ropinirole (as ropinirole hydrochloride)</p>
<p><span class="Bold">Inactive ingredients:</span> carboxymethylcellulose sodium, colloidal silicon dioxide, glycerol behenate, hydrogenated castor oil, hypromellose, lactose monohydrate, magnesium stearate, maltodextrin, mannitol, povidone, and one or more of the following: FD&amp;C Yellow No. 6 aluminum lake, FD&amp;C Blue No.2 aluminum lake, ferric oxides (black, red, yellow), polyethylene glycol 400, titanium dioxide.</p>
<p><br>Patient Information</p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span> (RE-qwip)</span></p>
<p><span class="Bold">(ropinirole)</span></p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Bold">If you have <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS), read this side.</span></p>
<p><span class="Bold">If you have Parkinsonâ€™s disease, read the other side.</span></p>
<table width="100%">
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Important Note: </span>REQUIP XL<span class="Sup">Â®</span> has not been studied in <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS) and is not approved for the treatment of RLS.</p></td></tr></tbody>
</table>
<p><span class="Bold">Read this information completely before you start taking REQUIP.</span> Read the information each time you get more medicine. There may be new information. This leaflet provides a summary about REQUIP. It does not include everything there is to know about your medicine. This information should not take the place of discussions with your healthcare provider about your medical condition or treatment with REQUIP.</p>
<p>People with RLS should take REQUIP differently than people with Parkinsonâ€™s disease (see â€œ<span class="Bold">How should I take REQUIP for RLS?â€?</span> for the recommended dosing for RLS). A lower dose is generally needed for people with RLS, and is taken once daily before bedtime.</p>
<p><span class="Bold">What is the most important information I should know about REQUIP?</span></p>
<p><span class="Bold">REQUIP can cause serious side effects, including:</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> You may experience a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> characterized by <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and/or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, mouth, tongue, or throat, which may cause problems in swallowing or breathing. <span class="Bold">If you experience any of these reactions </span>after starting REQUIP, you should not take REQUIP again until you talk to a healthcare provider and seek their advice.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Falling</span> asleep during normal activities.</span> You may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep while doing normal activities such as driving a car, doing physical tasks, or using hazardous machinery while taking REQUIP. You may suddenly <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> asleep without being drowsy or without warning. This may result in having <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span>. Your chances of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> asleep while doing normal activities while taking REQUIP are greater if you take other medicines that cause <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>.<span class="Bold"></span>Tell your healthcare provider right away if this happens. Before starting REQUIP, be sure to tell your healthcare provider if you take any medicines that make you drowsy.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Fainting</span>.</span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Fainting</span> can occur, and sometimes your heart rate may be decreased. This can happen especially when you start taking REQUIP or your dose is increased. Tell your healthcare provider if you <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or feel dizzy or light-headed.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Decrease in blood pressure.</span> REQUIP can decrease your blood pressure (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>), especially when you start taking REQUIP or when your dose is changed. If you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> or feel dizzy, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nauseated</span>, or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweaty</span> when you stand up from sitting or lying down (<span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>), this may mean that your blood pressure is decreased. When you change position from lying down or sitting to standing up, you should do it carefully and slowly. Call your healthcare provider if you have any of the symptoms of decreased blood pressure listed above. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in heart rate (decrease or increase).</span> REQUIP can decrease or increase your heart rate.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Unusual urges.</span> Some patients taking REQUIP get urges to behave in a way unusual for them. Examples of this are an unusual urge to gamble, increased sexual urges and behaviors, or an uncontrollable urge to shop, spend money, or eat. If you notice or your family notices that you are developing any unusual behaviors, talk to your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Increased chance of skin cancer (melanoma).</span> It is not known if REQUIP increases your chance of getting melanoma. You and your healthcare provider should check your skin on a regular basis. Tell your healthcare provider right away if you notice any changes in your skin such as a change in the size, shape, or color of moles on your skin. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Changes in <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> symptoms.</span> REQUIP may cause <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs</span> symptoms to come back in the morning (rebound), happen earlier in the evening, or even happen in the afternoon.</dd>
</dl>
<p><span class="Bold">What is REQUIP?</span></p>
<p>REQUIP is a prescription medicine containing ropinirole used to treat moderate-to-severe primary <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS). It is also used to treat Parkinsonâ€™s disease.</p>
<p>Having one of these conditions does not mean you have or will develop the other condition.</p>
<p>You should not be taking more than 1 medicine containing ropinirole. Tell your healthcare provider if you are taking any other medicine containing ropinirole.</p>
<p>It is not known if REQUIP is safe and effective for use in children younger than 18 years of age.</p>
<p><span class="Bold">Who should not take REQUIP?</span></p>
<p><span class="Bold">Do not take REQUIP if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>are allergic to ropinirole or any of the ingredients in REQUIP. See the end of this leaflet for a complete list of the ingredients in REQUIP. </dd>
</dl>
<p><span class="Bold">Call your healthcare provider and get help right away if you have any of the following symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, lips, mouth, tongue, or throat</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></span></dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking REQUIP?</span></p>
<p><span class="Bold">Before you take REQUIP, tell your healthcare provider if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">daytime sleepiness</span> from a <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span> or have unexpected or unpredictable <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> or periods of sleep.</dd>
<dt>â€¢</dt>
<dd>are taking any other prescription or over-the-counter medicines. Some of these medicines may increase your chances of getting side effects while taking REQUIP.</dd>
<dt>â€¢</dt>
<dd>start or stop taking other medicines while you are taking REQUIP. This may increase your chances of getting side effects.</dd>
<dt>â€¢</dt>
<dd>start or stop smoking while you are taking REQUIP. Smoking may decrease the treatment effect of REQUIP.</dd>
<dt>â€¢</dt>
<dd>feel dizzy, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nauseated</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweaty</span>, or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span> when you stand up from sitting or lying down.</dd>
<dt>â€¢</dt>
<dd>drink alcoholic beverages. This may increase your chances of becoming drowsy or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepy</span> while taking REQUIP.</dd>
<dt>â€¢</dt>
<dd>have high or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">low blood pressure</span>.</dd>
<dt>â€¢</dt>
<dd>have or have had heart problems.</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. REQUIP should only be used during pregnancy if needed.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding. It is not known if REQUIP passes into your breast milk. Talk to your healthcare provider to decide whether you will breastfeed or take REQUIP.</dd>
<dt>â€¢</dt>
<dd>have any other medical conditions.</dd>
</dl>
<p><span class="Bold">How should I take REQUIP for RLS?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take REQUIP exactly as directed by your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>The usual way to take REQUIP is once in the evening, 1 to 3 hours before bedtime.</dd>
<dt>â€¢</dt>
<dd>Your healthcare provider will start you on a low dose of REQUIP. Your healthcare provider may change the dose until you are taking the right amount of medicine to control your symptoms. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">If you miss your dose, do not double your next dose. </span>Take only your usual dose 1 to 3 hours before your next bedtime.</dd>
<dt>â€¢</dt>
<dd>Contact your healthcare provider if you stop taking REQUIP for any reason. Do not restart without consulting your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>You can take REQUIP with or without food.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of REQUIP?</span></p>
<p><span class="Bold">REQUIP can cause serious side effects, including: </span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">See â€œWhat is the most important information I should know about REQUIP?â€? </span></dd>
</dl>
<p>The most common side effects of REQUIP include:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></dd>
</dl>
<dl>
<dt>Â </dt>
<dd>Tell your healthcare provider if you have any side effect that bothers you or does not go away.</dd>
</dl>
<p>This is not a complete list of side effects and should not take the place of talking with your healthcare provider. Your healthcare provider or pharmacist can give you a more complete list of possible side effects.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store REQUIP?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store REQUIP at room temperature between 68F to 77F (20C to 25C).</dd>
<dt>â€¢</dt>
<dd>Keep REQUIP in a tightly closed container and out of direct sunlight.</dd>
</dl>
<p><span class="Bold">Keep REQUIP and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of REQUIP.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not take REQUIP for a condition for which it was not prescribed. Do not give REQUIP to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This side of the patient information leaflet summarizes the most important information about REQUIP for <span class="product-label-link" type="condition" conceptid="73754" conceptname="Restless legs">Restless Legs Syndrome</span> (RLS). If you would like more information, talk with your healthcare provider or pharmacist. You can ask your healthcare provider or pharmacist for information about REQUIP that is written for healthcare professionals. For more information go to www.gsk.com or call 1-888-825-5249 (toll-free).</p>
<p><span class="Bold">What are the ingredients in REQUIP?</span></p>
<p><span class="Bold">Active ingredient:</span> ropinirole (as ropinirole hydrochloride) </p>
<p><span class="Bold">Inactive ingredients:</span> croscarmellose sodium, hydrous lactose, magnesium stearate, microcrystalline cellulose, and one or more of the following: carmine, FD&amp;C Blue No. 2 aluminum lake, FD&amp;C Yellow No. 6 aluminum lake, hypromellose, iron oxides, polyethylene glycol, polysorbate 80, titanium dioxide.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>REQUIP and REQUIP XL are registered trademarks of the GSK group of companies.</p>
<p>GlaxoSmithKline</p>
<p>Research Triangle Park, NC 27709</p>
<p>Â©2014, the GSK group of companies. All rights reserved.</p>
<p>August 2014</p>
<p>REP:3PIL</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_1cea1f79-031c-4229-b52b-34d6c42dd4d8"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0007-4890-20</span></p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(rOPINIRole tablets)</span></p>
<p><span class="Bold">0.25 mg</span></p>
<p><span class="Bold">100 Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only </span></p>
<p>Each tablet contains 0.29 mg ropinirole HCl equivalent to 0.25 mg ropinirole. </p>
<p>Store at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [see USP].</p>
<p>Protect from light and moisture. Close container tightly after each use.</p>
<p><span class="Bold">Dosage: </span>See Prescribing Information for complete dosing instructions. </p>
<p><span class="Bold">GlaxoSmithKline</span></p>
<p>Research Triangle Park, </p>
<p>NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 9/11</p>
<p>10000000099522</p>
<div class="Figure">
<a name="id6969302"></a><img alt="Requip 0.25 mg 100 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de0bb94f-4fd8-4f27-5ba6-6f392dd5160f&amp;name=image-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_053894f5-6576-4da8-9a05-bf63d35ff9a5"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0007-4891-20</span></p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(rOPINIRole tablets)</span></p>
<p><span class="Bold">0.5 mg</span></p>
<p><span class="Bold">100 Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only </span></p>
<p>Each tablet contains 0.57 mg ropinirole HCl equivalent to 0.5 mg ropinirole. </p>
<p>Store at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [see USP].</p>
<p>Protect from light and moisture. Close container tightly after each use.</p>
<p><span class="Bold">Dosage: </span>See Prescribing Information for complete dosing instructions. </p>
<p><span class="Bold">GlaxoSmithKline</span></p>
<p>Research Triangle Park, </p>
<p>NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 9/11</p>
<p>10000000099523</p>
<div class="Figure">
<a name="id6969303"></a><img alt="Requip 0.5 mg 100 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de0bb94f-4fd8-4f27-5ba6-6f392dd5160f&amp;name=image-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5f74cf4f-ca27-4a59-b87b-6093e4e22458"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0007-4892-20</span></p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(rOPINIRole tablets)</span></p>
<p><span class="Bold">1 mg</span></p>
<p><span class="Bold">100 Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only </span></p>
<p>Each tablet contains 1.14 mg ropinirole HCl equivalent to 1 mg ropinirole. </p>
<p>Store at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [see USP].</p>
<p>Protect from light and moisture. Close container tightly after each use.</p>
<p><span class="Bold">Dosage: </span>See Prescribing Information for complete dosing instructions. </p>
<p><span class="Bold">GlaxoSmithKline</span></p>
<p>Research Triangle Park, </p>
<p>NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 9/11</p>
<p>10000000099524</p>
<div class="Figure">
<a name="id6969304"></a><img alt="Requip 1 mg 100 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de0bb94f-4fd8-4f27-5ba6-6f392dd5160f&amp;name=image-05.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_821f562f-dd2c-4205-a16f-f14821350557"></a><a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0007-4893-20</span></p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(rOPINIRole tablets)</span></p>
<p><span class="Bold">2 mg</span></p>
<p><span class="Bold">100 Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only </span></p>
<p>Each tablet contains 2.28 mg ropinirole HCl equivalent to 2 mg ropinirole. </p>
<p>Store at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [see USP].</p>
<p>Protect from light and moisture. Close container tightly after each use.</p>
<p><span class="Bold">Dosage: </span>See Prescribing Information for complete dosing instructions. </p>
<p><span class="Bold">GlaxoSmithKline</span></p>
<p>Research Triangle Park, </p>
<p>NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 9/11</p>
<p>10000000099525</p>
<div class="Figure">
<a name="id3717"></a><img alt="Requip 2 mg 100 count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de0bb94f-4fd8-4f27-5ba6-6f392dd5160f&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_fbd7ce43-1ad3-44d4-b8ad-e0b617f77eb5"></a><a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0007-4895-20</span></p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(rOPINIRole tablets)</span></p>
<p><span class="Bold">3 mg</span></p>
<p><span class="Bold">100 Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only </span></p>
<p>Each tablet contains 3.42 mg ropinirole HCl equivalent to 3 mg ropinirole. </p>
<p>Store at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [see USP].</p>
<p>Protect from light and moisture. Close container tightly after each use.</p>
<p><span class="Bold">Dosage: </span>See Prescribing Information for complete dosing instructions. </p>
<p><span class="Bold">GlaxoSmithKline</span></p>
<p>Research Triangle Park, </p>
<p>NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 9/11</p>
<p>10000000099526</p>
<div class="Figure">
<a name="id442635"></a><img alt="Requip 3 mg 100 ct label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de0bb94f-4fd8-4f27-5ba6-6f392dd5160f&amp;name=Requip%203%20mg%20100%20ct%20label.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_bf7ecfd0-8bd8-4d78-9d5f-afde51e1e183"></a><a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0007-4896-20</span></p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(rOPINIRole tablets)</span></p>
<p><span class="Bold">4 mg</span></p>
<p><span class="Bold">100 Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only </span></p>
<p>Each tablet contains 4.56 mg ropinirole HCl equivalent to 4 mg ropinirole. </p>
<p>Store at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [see USP].</p>
<p>Protect from light and moisture. Close container tightly after each use.</p>
<p><span class="Bold">Dosage: </span>See Prescribing Information for complete dosing instructions. </p>
<p><span class="Bold">GlaxoSmithKline</span></p>
<p>Research Triangle Park, </p>
<p>NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 9/11</p>
<p>10000000099527</p>
<div class="Figure">
<a name="id441048"></a><img alt="Requip 4 mg 100 ct label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de0bb94f-4fd8-4f27-5ba6-6f392dd5160f&amp;name=Requip%204%20mg%20100%20ct%20label.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_6244ed08-46e1-4bfb-9469-500167730f58"></a><a name="section-23"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><span class="Bold">NDC 0007-4894-20</span></p>
<p><span class="Bold">REQUIP<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(rOPINIRole tablets)</span></p>
<p><span class="Bold">5 mg</span></p>
<p><span class="Bold">100 Tablets </span></p>
<p><span class="Bold">R<span class="Sub">x</span> only </span></p>
<p>Each tablet contains 5.70 mg ropinirole HCl equivalent to 5 mg ropinirole. </p>
<p>Store at controlled room temperature 20<span class="Sup">o</span> to 25<span class="Sup">o</span>C (68<span class="Sup">o</span> to 77<span class="Sup">o</span>F) [see USP].</p>
<p>Protect from light and moisture. Close container tightly after each use.</p>
<p><span class="Bold">Dosage: </span>See Prescribing Information for complete dosing instructions. </p>
<p><span class="Bold">GlaxoSmithKline</span></p>
<p>Research Triangle Park, </p>
<p>NC 27709</p>
<p>Made in Ireland</p>
<p>Rev. 9/11</p>
<p>10000000099528</p>
<div class="Figure">
<a name="id439278"></a><img alt="Requip 5 mg 100 ct label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=de0bb94f-4fd8-4f27-5ba6-6f392dd5160f&amp;name=Requip%205%20mg%20100%20ct%20label.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REQUIPÂ 		
					</strong><br><span class="contentTableReg">ropinirole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0007-4890</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROPINIROLE HYDROCHLORIDE</strong> (ROPINIROLE) </td>
<td class="formItem">ROPINIROLE</td>
<td class="formItem">0.25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal (5 sided)) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;4890</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0007-4890-20</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020658</td>
<td class="formItem">10/10/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REQUIPÂ 		
					</strong><br><span class="contentTableReg">ropinirole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0007-4891</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROPINIROLE HYDROCHLORIDE</strong> (ROPINIROLE) </td>
<td class="formItem">ROPINIROLE</td>
<td class="formItem">0.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>INDIGOTINDISULFONATE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal (5 sided)) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;4891</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0007-4891-20</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020658</td>
<td class="formItem">10/10/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REQUIPÂ 		
					</strong><br><span class="contentTableReg">ropinirole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0007-4892</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROPINIROLE HYDROCHLORIDE</strong> (ROPINIROLE) </td>
<td class="formItem">ROPINIROLE</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal (5 sided)) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;4892</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0007-4892-20</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020658</td>
<td class="formItem">10/01/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REQUIPÂ 		
					</strong><br><span class="contentTableReg">ropinirole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0007-4893</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROPINIROLE HYDROCHLORIDE</strong> (ROPINIROLE) </td>
<td class="formItem">ROPINIROLE</td>
<td class="formItem">2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellowish-pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal (5 sided)) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;4893</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0007-4893-20</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020658</td>
<td class="formItem">10/03/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REQUIPÂ 		
					</strong><br><span class="contentTableReg">ropinirole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0007-4895</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROPINIROLE HYDROCHLORIDE</strong> (ROPINIROLE) </td>
<td class="formItem">ROPINIROLE</td>
<td class="formItem">3Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COCHINEAL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>INDIGOTINDISULFONATE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (moderate reddish-purple) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal (5 sided)) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;4895</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0007-4895-20</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020658</td>
<td class="formItem">06/19/2001</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REQUIPÂ 		
					</strong><br><span class="contentTableReg">ropinirole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0007-4896</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROPINIROLE HYDROCHLORIDE</strong> (ROPINIROLE) </td>
<td class="formItem">ROPINIROLE</td>
<td class="formItem">4Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>INDIGOTINDISULFONATE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (<span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> brown) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal (5 sided)) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;4896</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0007-4896-20</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020658</td>
<td class="formItem">09/21/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REQUIPÂ 		
					</strong><br><span class="contentTableReg">ropinirole tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0007-4894</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ROPINIROLE HYDROCHLORIDE</strong> (ROPINIROLE) </td>
<td class="formItem">ROPINIROLE</td>
<td class="formItem">5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (3 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>INDIGOTINDISULFONATE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (pentagonal (5 sided)) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SB;4894</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0007-4894-20</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020658</td>
<td class="formItem">10/10/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>GlaxoSmithKline LLC
							(167380711)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2ce65527-2c46-452f-80b2-0a1f67493fe0</div>
<div>Set id: de0bb94f-4fd8-4f27-5ba6-6f392dd5160f</div>
<div>Version: 9</div>
<div>Effective Time: 20140829</div>
</div>
</div>Â <div class="DistributorName">GlaxoSmithKline LLC</div></p>
</body></html>
